Google
OMER Stock Price & Analysis — Omeros Corporation (Healthcare >> Biotechnology)
OMER FAQ
What is OMER's P/E ratio?
Omeros Corporation (OMER) currently trades at a P/E ratio of 6.01.
What is OMER's ROE?
Omeros Corporation reports a Return on Equity (ROE) of -136.06%.
What is OMER's dividend yield?
Omeros Corporation offers a dividend yield of 0.00%.
What is OMER's Quality Score?
Our AI rates OMER's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OMER?
Our AI Timing Score for OMER is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OMER belong to?
Omeros Corporation is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
OMER AI Analysis Summary
Our AI summary for OMER: Omeros Corporation (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 6.01, ROE of -136.06%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 12.56
Price
0.72
(6.08%)
Day Change
|
|
|---|
OMER, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 12.56 |
| PBV / Sector |
-13.53 / 44,219.29
|
| Earning Per Share | 1.26 |
| PE / Sector |
6.01 / 19.28
GREAT
|
| PEG or PE/Growth / Sector |
-0.04 / 1.23
|
| Average 1M Daily Value |
15.16 M
GREAT
|
| Average 1W Daily Value |
18.66 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:57 |
| Symbol | OMER |
| Name | OMEROS CORPORATION |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 72.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 856.92 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: The Omeros Building, Seattle, WA, United States, 98119
Phone: 206 676 5000
Website: https://www.omeros.com
Employees: 175
Sector: Healthcare >> Biotechnology
Description: Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap